Loading…
← CockpitCompetitor Analysis › 4565.T Nxera Pharma Co., Ltd.Open in the cockpit ↗

Nxera Pharma Co., Ltd.4565.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum leader 99
Mkt cap
$974M
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$24.6M
20-day average traded
Fwd P/E
25.8×
forward earnings
ROIC−WACC
-2.2 pp
WACC 5.5%
Hurdle
-10 pp
Req g minus delivered
Next earnings
90 days
16 Feb 2027
Close · JPY¥1,708
1D-2.1%
1W-5.7%
1M+40.5%
3M+54.6%
6M+45.7%
YTD+106.5%
1Y+112.7%
ATR %5.4%
52w lowhigh9.1% off high

What Nxera Pharma does

Employees: 382

Nxera Pharma at a glance

Size Nxera Pharma (4565.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $974M, the 751st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,708 on 18 Nov 2026.

Performance Over six months the shares gained 45.7%, against -11.1% for the median peer and -1.4% for the Japan market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 23.7% over the last twelve months (peer median +2.8%); the operating margin is 13.6% (peer median 8.7%).

Valuation It trades at 25.8× forward earnings against a peer median of 20.6× (4th most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.2 points below its cost of capital (5.5% WACC).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 20264565.T 152Peer median 90
Six months, rebased to 100: Nxera Pharma against the median of its 20 peers (local-currency closes).

Nxera Pharma financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥35.5B¥29.6B¥28.8B¥12.8B¥15.6B
Revenue growth—+3%+126%-18%—
Gross profit¥28.1B¥18.0B¥18.1B¥7.87B¥13.8B
EBITDA¥9.17B-¥3.71B-¥1.38B-¥6.58B¥4.16B
Net income-¥5.39B-¥12.5B-¥4.84B-¥7.19B¥382M
Free cash flow¥5.01B-¥3.12B-¥8.24B-¥6.08B¥9.68B
Capital expenditure¥5.85B¥625M¥1.54B¥851M¥303M
Total debt¥52.0B¥57.4B¥67.9B¥74.0B¥29.7B

Quarterly statements and history in the cockpit →

Nxera Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%+40%PGHLSPTX600129688382AARTIPHARM688759600557300294688710200560511668809160353800243748873007024565.T6-month return →1-month return →
Up and to the right = strong over both horizons. Nxera Pharma is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%20×40×60×PGHL6001296005573002946887102005605116STAR60353848870006503007024565.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nxera Pharma is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%PGHL6883826005576887102005605116STAR6035380024376002520006504565.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nxera Pharma is the large dot.

Nxera Pharma competitors and peer comparison

How Nxera Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nxera Pharma against its 20 peers (data as of 18 Nov 2026)
Measure4565.TPeer medianRank in peer set
1-month return+40.5%-6.5%highest of 21
6-month return+45.7%-11.1%highest of 21
Distance from 52-week high-9.1%-35.0%2nd highest of 21
Revenue growth (TTM)+23.7%+2.8%4th highest of 19
Operating margin13.6%8.7%7th highest of 19
Forward P/E25.8×20.6×4th most expensive of 13
Growth the price implies (Req g, 7 yrs)17.7%6.0%most demanding of 13
Growth delivered (Del g)+27.3%+2.6%highest of 13
Hurdle (Req g minus delivered)-9.7 pp+1.8 pp2nd least demanding of 13
ROIC minus cost of capital-2.2 pp-0.8 pp6th lowest of 19
EV / EBITDA20.8×11.1×most expensive of 6
Net debt / EBITDA3.9×1.8×most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
SSY 2005.HKHong Kong$948M+8%-4%12%12.5×2.3%-0.5%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%15.9×17.6%+7.8%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%42.3×11.6%+4.9%
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%n/a7.7%-6.9%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%n/an/an/a
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%n/a10.3%-13.7%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%

Questions

Which companies are Nxera Pharma's closest peers?
The cockpit's peer set: Procter & Gamble Health (PGHL.NS), Seaport Therapeutics (SPTX), Chongqing Taiji Industry (Group) (600129.SS), InventisBio (688382.SS), Aarti Pharmalabs (AARTIPHARM.NS), BeBetter Med (688759.SS), Jiangsu Kanion Pharmaceutical (600557.SS), China Resources Boya Bio-pharmaceutical (300294.SZ).
Is Nxera Pharma expensive compared with its peers?
On forward p/e it trades at 25.8× against a peer median of 20.6×, 4th most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Nxera Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +45.7% against -11.1% for the median peer; over one year +112.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.